Dynavax Technologies Co. (NASDAQ:DVAX) Stake Boosted by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company increased its stake in Dynavax Technologies Co. (NASDAQ:DVAX) by 6.4% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 67,854 shares of the biopharmaceutical company’s stock after purchasing an additional 4,069 shares during the quarter. The Manufacturers Life Insurance Company owned approximately 0.05% of Dynavax Technologies worth $762,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of the stock. Millennium Management LLC purchased a new position in Dynavax Technologies in the 2nd quarter worth about $17,615,000. Great Point Partners LLC grew its stake in Dynavax Technologies by 87.7% during the 2nd quarter. Great Point Partners LLC now owns 2,374,000 shares of the biopharmaceutical company’s stock valued at $26,660,000 after acquiring an additional 1,109,080 shares in the last quarter. Marshall Wace LLP purchased a new position in Dynavax Technologies during the 2nd quarter valued at about $902,000. Bank of Montreal Can grew its stake in Dynavax Technologies by 15.2% during the 2nd quarter. Bank of Montreal Can now owns 994,632 shares of the biopharmaceutical company’s stock valued at $11,309,000 after acquiring an additional 130,893 shares in the last quarter. Finally, Public Sector Pension Investment Board grew its stake in Dynavax Technologies by 8.7% during the 2nd quarter. Public Sector Pension Investment Board now owns 287,958 shares of the biopharmaceutical company’s stock valued at $3,234,000 after acquiring an additional 23,012 shares in the last quarter. Hedge funds and other institutional investors own 96.96% of the company’s stock.

Dynavax Technologies Stock Performance

Shares of NASDAQ DVAX opened at $10.46 on Tuesday. The company has a quick ratio of 13.18, a current ratio of 14.18 and a debt-to-equity ratio of 0.35. The business’s 50 day moving average is $11.03 and its two-hundred day moving average is $11.30. The company has a market cap of $1.37 billion, a P/E ratio of 174.33 and a beta of 1.37. Dynavax Technologies Co. has a 12 month low of $9.74 and a 12 month high of $15.15.

Dynavax Technologies (NASDAQ:DVAX) last issued its earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.08 EPS for the quarter, beating analysts’ consensus estimates of $0.06 by $0.02. The business had revenue of $73.80 million during the quarter, compared to analyst estimates of $76.92 million. Dynavax Technologies had a return on equity of 2.76% and a net margin of 6.88%. During the same period in the prior year, the company posted $0.03 earnings per share. On average, equities analysts expect that Dynavax Technologies Co. will post 0.16 EPS for the current year.

Wall Street Analysts Forecast Growth

DVAX has been the subject of several research reports. The Goldman Sachs Group reduced their price target on Dynavax Technologies from $20.00 to $15.00 and set a “neutral” rating for the company in a report on Thursday, August 8th. HC Wainwright reiterated a “buy” rating and set a $29.00 price target on shares of Dynavax Technologies in a report on Wednesday, August 7th. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $23.67.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.